D
Diego Malón
Publications - 9
Citations - 43
Diego Malón is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 36 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant chemotherapy for stages II, III and IV of colon cancer.
Cristina Grávalos,Ignacio García-Escobar,Pilar García-Alfonso,Javier Cassinello,Diego Malón,Alfredo Carrato +5 more
TL;DR: The role of monoclonal antibodies, cetuximab and bevacizumab, combined with oxaliplatin/fluoropyrimidine-based CT is under investigation in clinical trials and the best alternatives are capecitabine or continuous infusion of 5FU/LV.
Journal ArticleDOI
Biliary cystadenocarcinoma with mesenchymal stroma.
TL;DR: The diagnostic evaluation, surgical management, pathological characteristics, treatment and follow-up of one patient with hepatobiliary cystadenocarcinoma with ovarian stroma is described.
Journal ArticleDOI
FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
María Gaibar,Apolonia Novillo,Alicia Romero-Lorca,Diego Malón,Beatriz Antón,Amalia Moreno,Ana Fernández-Santander +6 more
TL;DR: Although based on a small sample size, the findings suggest that patients with FGFR1 amplification might benefit less from anti-HER2 antibody therapy, compared with those who receive chemotherapy as neoadjuvant treatment.
Journal ArticleDOI
Abstract OT2-20-01: Rogaratinib, palbociclib and fulvestrant in advanced hormone receptor-positive (HR+), FGFR1/2-positive breast cancer: Phase I trial plus an expansion cohort
Sonia Pernas,Cristina Hernando,Begoña Bermejo,Noelia Martínez-Jañez,José Ángel García Sáenz,Serafin Morales,Luis Manso,JO Coppede Da Silva,Juan Antonio Guerra,Diego Malón,Silvana Mouron,Eduardo Caleiras,Miguel Quintela-Fandino +12 more
TL;DR: This trial will test the safety and toxicity of the triple blockade combining fulvestrant, palbociclib and rogaratinib and study its role as a resistant-reversion combo for FGFR1/2-positive, HR+ patients progressing to a CDK4/6 inhibitor plus aromatase inhibitor (AI) in the first-line metastatic setting.
Journal ArticleDOI
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer
Silvana Mouron,Maria J. Bueno,Manuel Muñoz,Raul M. Torres,Sandra Rodríguez,Juan V. Apala,JO Coppede Da Silva,Rodrigo Sánchez-Bayona,Luis Manso,Juan Antonio Guerra,Laura Rodríguez-Lajusticia,Diego Malón,Marcos Malumbres,Miguel Quintela-Fandino +13 more
TL;DR: In this paper , the p27Kip1 V109G single-nucleotide polymorphism was found to be homozygous in approximately 15% of hormone-positive breast cancer patients.